Corticosteroids in adult respiratory distress syndrome - an inconvenient truth?
Int J Pharm Pract
; 29(6): 642-644, 2021 Dec 04.
Article
in English
| MEDLINE | ID: covidwho-1381009
ABSTRACT
OBJECTIVES:
Recent studies have demonstrated mortality benefits from corticosteroid use in COVID-19 patients requiring respiratory support. However, clinical practice may warrant the use of corticosteroids outside the context of a clinical trial. Such data are rarely, if ever, reported. We explored the use of corticosteroids for adult respiratory distress syndrome (ARDS) indications in patients with non-COVID ARDS.METHODS:
We retrospectively studied patients with moderate-to-severe ARDS, admitted to our intensive care unit (ICU) between January 2018 and March 2020. KEYFINDINGS:
Of the 91 patients with ARDS identified, 80% were treated with a corticosteroid during their ICU admission. Of these, 73 (82%) had corticosteroids administered for reasons other than ARDS.CONCLUSIONS:
Corticosteroid use for non-ARDS indications is commonplace in ARDS patients in our ICU. The use of corticosteroids outside a randomisation process in randomised clinical trials may be more common than appreciated and needs to be routinely reported.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiratory Distress Syndrome
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Adult
/
Humans
Language:
English
Journal:
Int J Pharm Pract
Journal subject:
Pharmacy
Year:
2021
Document Type:
Article
Affiliation country:
Ijpp
Similar
MEDLINE
...
LILACS
LIS